177 related articles for article (PubMed ID: 34253424)
21. Prognostic significance of tumor multifocality in papillary thyroid carcinoma and its relationship with primary tumor size: a retrospective study of 2,309 consecutive patients.
Kim KJ; Kim SM; Lee YS; Chung WY; Chang HS; Park CS
Ann Surg Oncol; 2015 Jan; 22(1):125-31. PubMed ID: 25092159
[TBL] [Abstract][Full Text] [Related]
22. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
[TBL] [Abstract][Full Text] [Related]
23. Predicting Factors for Bilaterality in Papillary Thyroid Carcinoma with Tumor Size <4 cm.
Kim SK; Park I; Woo JW; Lee JH; Choe JH; Kim JH; Kim JS
Thyroid; 2017 Feb; 27(2):207-214. PubMed ID: 27750022
[TBL] [Abstract][Full Text] [Related]
24. Total tumor diameter: the neglected value in papillary thyroid microcarcinoma.
Feng JW; Pan H; Wang L; Ye J; Jiang Y; Qu Z
J Endocrinol Invest; 2020 May; 43(5):601-613. PubMed ID: 31749082
[TBL] [Abstract][Full Text] [Related]
25. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
[TBL] [Abstract][Full Text] [Related]
26. Multifocality, but not bilaterality, is a predictor of disease recurrence/persistence of papillary thyroid carcinoma.
Kim HJ; Sohn SY; Jang HW; Kim SW; Chung JH
World J Surg; 2013 Feb; 37(2):376-84. PubMed ID: 23135422
[TBL] [Abstract][Full Text] [Related]
27. Multifocality related factors in papillary thyroid carcinoma.
Gur EO; Karaisli S; Haciyanli S; Kamer E; Genc H; Atahan K; Haciyanli M
Asian J Surg; 2019 Jan; 42(1):297-302. PubMed ID: 30585170
[TBL] [Abstract][Full Text] [Related]
28. Risk Factors for Central Neck Lymph Node Metastases in Micro- Versus Macro- Clinically Node Negative Papillary Thyroid Carcinoma.
Sessa L; Lombardi CP; De Crea C; Tempera SE; Bellantone R; Raffaelli M
World J Surg; 2018 Mar; 42(3):623-629. PubMed ID: 29238850
[TBL] [Abstract][Full Text] [Related]
29. Is Multifocality a Predictor of Poor Outcome in Childhood and Adolescent Papillary Thyroid Carcinoma?
Scholfield DW; Lopez J; Eagan A; Antal Z; Tuttle RM; Ghossein R; LaQuaglia M; Shaha AR; Shah JP; Wong RJ; Patel SG; Ganly I
J Clin Endocrinol Metab; 2023 Nov; 108(12):3135-3144. PubMed ID: 37350510
[TBL] [Abstract][Full Text] [Related]
30. A quantitative assessment of the number of disease foci in papillary thyroid cancer.
Evans Harding N; Simo R; Li L; Maniam P; Adamson R; Hay A; Conn B; Lyall M; Nixon IJ
Eur J Surg Oncol; 2023 Jul; 49(7):1141-1146. PubMed ID: 37024371
[TBL] [Abstract][Full Text] [Related]
31. Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.
Genpeng L; Jianyong L; Jiaying Y; Ke J; Zhihui L; Rixiang G; Lihan Z; Jingqiang Z
Medicine (Baltimore); 2018 Feb; 97(5):e9619. PubMed ID: 29384841
[TBL] [Abstract][Full Text] [Related]
32. Level V Metastasis, a Novel Predicative Factor for Recurrence in N1b Papillary Thyroid Carcinoma.
Wu Y; Li J; Wu X; Dai L
Curr Pharm Des; 2018; 24(5):559-563. PubMed ID: 28990528
[TBL] [Abstract][Full Text] [Related]
33. Radioactive iodine in low- to intermediate-risk papillary thyroid cancer.
Zhao H; Gong Y
Front Endocrinol (Lausanne); 2022; 13():960682. PubMed ID: 36034423
[TBL] [Abstract][Full Text] [Related]
34. Number of tumor foci predicts prognosis in papillary thyroid cancer.
Qu N; Zhang L; Ji QH; Zhu YX; Wang ZY; Shen Q; Wang Y; Li DS
BMC Cancer; 2014 Dec; 14():914. PubMed ID: 25471041
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of tumor size and minimal extrathyroidal extension in papillary thyroid carcinoma.
Shin CH; Roh JL; Song DE; Cho KJ; Choi SH; Nam SY; Kim SY
Am J Surg; 2020 Oct; 220(4):925-931. PubMed ID: 32081409
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the clinicopathologic features and prognosis of bilateral versus unilateral multifocal papillary thyroid cancer: An updated study with more than 2000 consecutive patients.
Wang W; Su X; He K; Wang Y; Wang H; Wang H; Zhao Y; Zhao W; Zarnegar R; Fahey TJ; Teng X; Teng L
Cancer; 2016 Jan; 122(2):198-206. PubMed ID: 26506214
[TBL] [Abstract][Full Text] [Related]
37. Bilaterality, not multifocality, is an independent risk factor for recurrence in low-risk papillary thyroid cancer.
Rodriguez Schaap PM; Lin JF; Metman MJH; Dreijerink KMA; Links TP; Bonjer HJ; Nieveen van Dijkum EJM; Dickhoff C; Kruijff S; Engelsman AF
J Natl Cancer Inst; 2023 Sep; 115(9):1071-1076. PubMed ID: 37267155
[TBL] [Abstract][Full Text] [Related]
38. Lateral neck metastases in the ipsilateral and contralateral compartments of papillary thyroid carcinoma located in one lobe.
Kim SY; Kim SM; Chang H; Kim BW; Lee YS; Chang HS; Park CS
ANZ J Surg; 2019 Nov; 89(11):E498-E501. PubMed ID: 31566299
[TBL] [Abstract][Full Text] [Related]
39. Association of adjuvant radioactive iodine therapy with survival in node-positive papillary thyroid cancer.
Sun Y; Gong J; Guo B; Shang J; Cheng Y; Xu H
Oral Oncol; 2018 Dec; 87():152-157. PubMed ID: 30527231
[TBL] [Abstract][Full Text] [Related]
40. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases.
Matsuzu K; Sugino K; Masudo K; Nagahama M; Kitagawa W; Shibuya H; Ohkuwa K; Uruno T; Suzuki A; Magoshi S; Akaishi J; Masaki C; Kawano M; Suganuma N; Rino Y; Masuda M; Kameyama K; Takami H; Ito K
World J Surg; 2014 Jan; 38(1):68-79. PubMed ID: 24081532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
